Scilex Holding Company announces completion of commercial manufacturing of GloperbaŽ | SRNE Message Board Posts


Sorrento Therapeutics, Inc.

  SRNE website

SRNE   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message    Post Message    Post a Reply return to message boardtop of board
Msg  1943 of 2010  at  11/27/2023 9:12:36 AM  by

put_lipstick_on_this_pig


Scilex Holding Company announces completion of commercial manufacturing of GloperbaŽ

 

Scilex Holding Company announces completion of commercial manufacturing of Gloperba® with the brand marketed and distributed under Scilex Pharmaceuticals, Inc. and is expecting to Launch in the U.S. in the first quarter of 2024

 
 
  • Gloperba® is the first and only liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.

  • Gout is a painful arthritic disorder affecting an estimated 9.2 million people in the United States1. As gout cases increase every year, treatment requirements increase. The gout treatment market is projected to be $2.0 billion in the U.S. by 2028 with a well-defined area of unmet need.2

  • Scilex is well-positioned to market and distribute Gloperba®:

    • Scilex has a direct distribution network to national and regional wholesalers and pharmacies throughout the U.S.

    • Scilex has an experienced commercial and managed care team that has successfully launched and grown market access for ZTlido® (lidocaine topical system) to more than 225 million covered lives in the U.S. as well as successfully launching Elyxyb® (celecoxib oral solution) in the U.S. in April 2023, the only FDA-approved ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults.

PALO ALTO, Calif., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced that it has completed commercial manufacturing of Gloperba®, an FDA-approved prophylactic treatment for painful gout flares in adults, in the U.S. and is expecting to launch Gloperba® in the U.S. in the first quarter of 2024.

Gloperba® is a highly complementary commercial asset that allows the Company to provide physicians with another tool in their non-opioid pain management armamentarium to treat gout earlier in the patient journey as the Company continues to work towards re-defining the role of opioids as a last resort rescue medication.

 


     e-mail to a friend      printer-friendly     add to library      
|  
Recs: 2  
   Views: 0 []
Previous Message  Next Message    Post Message    Post a Reply return to message boardtop of board




Financial Market Data provided by
.
Loading...